Annovis Bio, Inc. (ANVS) Stock Price & Analysis
Annovis Bio, Inc. (ANVS) — MoonshotScore 29/100 (Weak band), calculated Nov 18, 2026. Price $0.841 (+13.16%), as of the Nov 18, 2026 trading session; market cap $52.2M.
Educational signal · not a buy or sell recommendation · How to read this
Annovis Bio, Inc. · ANVS · NYSE
Annovis Bio, Inc. is a clinical-stage drug platform company focused on developing treatments for neurodegenerative diseases. Their lead compound, Buntanetap, targets Alzheimer's and Parkinson's diseases and is currently in clinical trials.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Annovis Bio (ANVS)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fragile balance sheet, stalling growth and an expensive valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Average; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Shrinking; Momentum: Slipping.
Earnings yield is the main valuation drag relative to sector peers.
- EPS beat 0 of the last 4 reports
- Altman Z -0.84 · Piotroski F 0
Holding back: balance-sheet strain, a rich price, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 30 | Weak | |
| 27 | Weak | |
| 28 | Weak | |
| 28 | Weak | |
| 29 | Weak | |
| 29 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.841 | |
| Change on the day | +13.16% | |
| 52-week range | $0.6161 – $5.50 | |
| Market capitalisation | $52.2M | — |
| Price / earnings (trailing) | -1.38 | |
| Shares traded on the day | 1.31M |
Price & events
Other perspectives
Council score for Annovis Bio (ANVS): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Englander-style lens and Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens disagrees with the Valuation pillar (Bubble, 2 of 100): it reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Annovis Bio (ANVS), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Annovis Bio, Inc. (ANVS) is listed on NYSE. It employs 7 people and is led by Maria L. Maccecchini. The market values it at $52.2M.
What do the latest results show for Annovis Bio (ANVS)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
What are the financial strengths and risks for Annovis Bio (ANVS)?
Short answer
What is holding it back is balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -0.84 · Piotroski F 0. Trailing ratios: current ratio 3.47.
Data-derived red flags
- Listing risk — at $0.841 the shares sit below the $1.00 minimum bid NYSE requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -0.84 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
What should you watch next at Annovis Bio (ANVS)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $10.95M · EPS -1.36 · 3 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- No quarterly income statement is held for ANVS.
Checked against the records this page reads, on the dates shown above.
How does Annovis Bio compare with its peers?
Short answer
Annovis Bio's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1382.75 Nov 18, 2026 | $1.23T | 98 5-pillar Nov 18, 2026 | |
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 | |
| $3.13 Nov 19, 2026 | $481M | 60 5-pillar Nov 18, 2026 | |
| Annovis Bio (ANVS) — this page | $0.841 | $52.2M | 29 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $10.95M
- EPS estimate
- $-1.36
Measured against a quoted price of $0.841 (as of Nov 18, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ANVS in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ANVS in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Annovis Bio (ANVS)?
Common Questions About ANVS
These answers are editorial: 1 of these 9 answers is drawn from the ANVS research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ANVS?
ANVS carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Annovis Bio, Inc. is a clinical-stage drug platform company focused on developing treatments for neurodegenerative diseases.
Is ANVS a good stock to buy?
Stock Expert AI does not rate ANVS buy, sell or hold. Annovis Bio, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ANVS stock price today?
The last price recorded for Annovis Bio, Inc. (ANVS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about ANVS stock?
As a clinical-stage biotechnology company, Annovis Bio's stock performance is highly dependent on the success of its clinical trials. Analysts' opinions are likely to be divided, reflecting the inherent uncertainty of drug development.
What are the key factors to evaluate for ANVS?
Annovis Bio, Inc. (ANVS) holds a MoonshotScore in the low range. Annovis Bio is also exploring the potential of Buntanetap in treating Alzheimer's disease in individuals with Down Syndrome. Not financial advice.
How frequently does ANVS data refresh on this page?
ANVS's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ANVS's recent stock price performance?
Annovis Bio, Inc. (ANVS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel drug candidates targeting the underlying mechanisms of neurodegenerative diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ANVS overvalued or undervalued right now?
Annovis Bio, Inc. (ANVS) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ANVS?
Fractional-share availability for Annovis Bio, Inc. (ANVS) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 6 from Financial Modeling Prep (FMP), 9 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com